3 Best Biotech Stocks to Buy Now, 11/12/2025, According to Top Analysts
Biotech is heating up—again. After a brutal 2024, the sector's bouncing back with breakthrough therapies and FDA fast-tracks. Here are the three stocks top analysts are betting on before year-end.
1. The Gene-Editing Powerhouse
CRISPR Therapeutics (CRSP) just bypassed phase 3 trial delays with a surprise FDA nod. Their sickle-cell treatment could hit $2B in sales by 2026—if insurers don’t throw a tantrum over pricing.
2. The Alzheimer’s Dark Horse
Cassava Sciences (SAVA) cut through amyloid-beta dogma with phase 2 data showing 34% cognitive improvement. Short sellers are still screaming ‘fraud,’ but institutional inflows tell a different story.
3. The mRNA Second Act
Moderna (MRNA) isn’t just a COVID play anymore. Their personalized cancer vaccine just doubled progression-free survival in melanoma trials. Wall Street’s whispering ‘blockbuster’—and hiking price targets by 40%.
Remember: These picks come from analysts who somehow still have jobs after missing every biotech crash since 2021. Do your own DD before riding the volatility rollercoaster.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
For more stock ideas, check out TipRanks’ Analyst Top Stocks tool, which tracks the latest Buy ratings from top analysts in real time.
Here are today’s top analyst-backed stock picks. Click on any ticker to research the company before deciding whether to add it to your portfolio.
(PASG) – This is a clinical-stage biotech company developing gene therapies for rare genetic brain diseases. Today, Chardan Capital analyst Geulah Livshits maintained a Buy rating on the stock with a price target of $21 per share. In the last three months, all three Top Analysts covering the stock have rated it a Buy. Taken together, their 12-month price targets imply an upside of about 400%.
(BNTX) – This is a biotechnology company that develops immunotherapies and vaccines using messenger RNA (mRNA) technology. Today, Jefferies analyst Akash Tewari maintained a Buy rating on the stock with a price target of $151 per share. Interestingly, seven out of the nine Top Analysts who recently rated the stock gave it a Buy. Taken together, their 12-month price targets imply an upside of about 29.37%.
(UPB) – Upstream Bio is a clinical-stage biotech company developing therapies for respiratory and inflammatory diseases. Yesterday, Truist Financial analyst Danielle Brill maintained a Buy rating on the stock. In the last three months, all four Top Analysts covering the stock have rated it a Buy. Taken together, their 12-month price targets imply an upside of about 215.4%.
Who Are the Top Analysts?
TipRanks ranks financial analysts according to the success rates of their ratings and the average return on each of their ratings. The Top Analysts have each earned a five-star ranking, thanks to the accuracy and profitability of their ratings over time.
